In an open-label randomized controlled trial of 275 HER2+ patients aged 70–80 years with breast cancer, trastuzumab monotherapy had a survival loss of <1 month but lower toxicity and higher health-related quality of life compared with trastuzumab plus chemotherapy (15). The gene discussed is ERBB2; the disease is breast carcinoma.